Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma

Cutaneous Malignant Melanoma Clinical Trial

Official title:

Comparative Microarray Analysis of microRNA Expression Profiles in Primary Cutaneous Malignant Melanoma, Cutaneous Malignant Melanoma Metastases and Benign Melanocytic Naevi

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01482260
• Other study ID #: microRNA5
• Status: Completed
• Phase: N/A
• First received: November 26, 2011
• Last updated: November 5, 2012
• Start date: December 2011

Study information

• Verified date: November 2012
• Source: Ruhr University of Bochum
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Observational

Clinical Trial Summary

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). This study will be an exploratory analysis by miRNA expression profiling using microarrays.

Description:

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). With regards to a rapidly growing number of newly discovered miRNA sequences, the availability of up-to-date miRNA expression profiles for primary cutaneous malignant melanoma (PCMM), cutaneous malignant melanoma metastases (CMMM) and benign melanocytic naevi (BMN) is limited. Patients with PCMM, CMMM and BMN are included in the study to perform an exploratory analysis by miRNA expression profiling using microarrays. Expression levels of miRNA candidates will be validated by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 1 Year and older

Eligibility

Inclusion Criteria:

• Primary Cutaneous Malignant Melanoma

• Cutaneous Malignant Melanoma Metastases

• Benign Melanocytic Naevi

Exclusion Criteria:

• Other Skin Cancer than Primary Cutaneous Malignant Melanoma

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cutaneous Malignant Melanoma
• Melanoma

Intervention

Procedure:
• Biopsy
Biopsy

Locations

Country	Name	City	State
Germany	Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum	Bochum	NRW

Sponsors (1)

Lead Sponsor	Collaborator
Ruhr University of Bochum

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Sand M, Skrygan M, Sand D, Georgas D, Gambichler T, Hahn SA, Altmeyer P, Bechara FG. Comparative microarray analysis of microRNA expression profiles in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases, and benign melanocytic n — View Citation